Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma

Table 1 Growth inhibition of colon carcinoma 26 by immunoconjugate 3G11-LDM in mice

Groups	Doses (mg/kg)	Mice number (begin/end)	BWC (g)	Tumor volume (cm3) mean±SD	Inhibition rate (%)
Control		10/10	0.5	1.0±0.20
3G11	0.75	10/10	0.6	0.8±0.20	25.7b
LDM	0.05	10/10	-0.2	0.4±0.16	56.4b
3G11+	0.75	10/10	-0.3	0.7±0.13	38.6b
LDM	+0.05
3G11-LDM	0.025	10/10	-0.4	0.5±0.09	54.5ab
3G11-LDM	0.05	10/10	-0.3	0.3±0.06	70.3ab
3G11-LDM	0.1	10/10	-0.3	0.2±0.06	81.2ab

^aP<0.05 vs LDM;

^bP<0.01 vs control; BWC = body weight change.